Skip to content

Medical errors in laboratory medicine

Medical errors in laboratory medicine are a serious problem that can have far-reaching consequences for patients. According to a study by the Medical Service of the National Association of Statutory Health Insurance Funds (MDS) from 2022, about 62% of all errors in the diagnostic process occur in the pre-analytical phase, i.e., before the sample even reaches the laboratory[1]. This underscores the importance of careful sample collection and handling. A common cause of medical errors in laboratory medicine is a lack of communication between the various parties involved. Dr. Maria Kletecka-Pulker, a lawyer and managing director of the Institute for Ethics and Law in Medicine at the University of Vienna, emphasizes that insufficient patient information about possible risks and side effects of examinations is a major problem[5]. This can lead to false expectations and misunderstandings. Organizational deficiencies also play a significant role. An analysis of 600 allegations of treatment errors showed that in 13% of cases...

more »Medical errors in laboratory medicine

Lauterbach was also an architect of the drug crisis

The drug shortage in Germany has developed into a serious problem in recent years. According to the Federal Institute for Drugs and Medical Devices (BfArM), supply bottlenecks were reported for 514 prescription-only medications in December 2023[3]. Particularly affected are fever syrups for children, painkillers, antibiotics, and even cancer medications. The actual number is likely to be even higher due to reporting delays. A main reason for this crisis is the so-called "cheap mentality" in the German healthcare system. Reforms by former SPD Health Minister Ulla Schmidt, in which the current Health Minister Karl Lauterbach acted as an advisor, led to extreme price pressure on pharmaceutical manufacturers[2]. As a result, many producers relocated their manufacturing abroad, particularly to China and India. Kai Joachimsen from the Association of the Pharmaceutical Industry points out that about 90 percent of all antibiotics now come from China[1]. The situation has dramatically escalated in recent years. While in 2018 there were still 265...

more »Lauterbach was also an architect of the drug crisis

Atomic Antibiotics Developed by Czech Scientists Counter Bacterial Resistance

Scientists from Palacký University Olomouc (UP) and the Technical University of Ostrava (VSB-TUO), in collaboration with colleagues from China, have discovered a groundbreaking method for developing a new generation of antibiotics. These antibiotics not only combat a wide range of bacteria but also effectively prevent the development of bacterial resistance. By employing atomic engineering, the researchers transformed manganese—a trace element vital for human health—into a potent antibiotic by embedding it in the structure of chemically modified graphene. Tests conducted on animal models have demonstrated the material’s significant potential, particularly in localized therapies such as wound healing. The discovery has been published in the prestigious journal Advanced Materials, and the team has filed a European patent to safeguard their innovation. "The material we developed successfully kills and inhibits the growth of all bacteria we studied, including highly resistant pathogens. It operates…

more »Atomic Antibiotics Developed by Czech Scientists Counter Bacterial Resistance

Switzerland: New LabWEB Functions at Bioanalytica

Bioanalytica recently introduced new features in their LabWEB system to improve usability and efficiency for their customers[1][2]. Main Innovations Extended Search Function.The search function has been optimized to enable faster and more precise patient searches. Users can now search for specific patient information more efficiently[2]. Improved Display of Results.The display of laboratory results has been revised to ensure a clearer and more easily understandable presentation. This facilitates the interpretation of results for medical professionals[2]. New Filtering Options.Additional filtering options have been introduced, allowing for more targeted selection and display of laboratory results. This improves the handling of large amounts of data[2]. Benefits for Users The new features in Bioanalytica's LabWEB system aim to optimize the workflow for medical personnel and increase efficiency in managing and analyzing laboratory results[2]. These improvements underscore Bioanalytica's commitment to continuously developing its digital services and adapting them to the needs of its… 

more »Switzerland: New LabWEB Features at Bioanalytica

Lausitz relies on GreenPharming

Research and society face the challenge of finding resource-efficient solutions for the production of biological medicines. So-called "GreenPharming" refers to the plant-based production of active ingredients for drug manufacturing. It is now being used for the first time in a scientific project in Lusatia. The goal is to make drug production more resource-efficient and thus more sustainable and environmentally friendly in the future. This is to be achieved with biogenic, i.e., plant-based, raw materials. GreenPharming is part of a visionary strategy to overcome numerous current challenges. In Lusatia, tobacco plants, Nicotiana benthamiana, will initially be cultivated. After harvesting, they will be processed into medicines in a completely integrated circular economy using renewable energies, making them climate-neutral. Another focus of the project is the production of therapeutic antibodies. For this purpose, the tobacco plants are intended to produce active ingredient proteins via biosynthesis under realistic laboratory conditions. Compared to conventional methods, such as… 

more »Lusatia relies on GreenPharming

Foreign investors take over German laboratory diagnostics industry

The German laboratory diagnostics market has undergone a significant transformation in recent years, with foreign investors showing increasing interest in German companies in this sector. This trend reflects the ongoing internationalization and consolidation of the industry. Significant Acquisitions by Foreign Investors One of the most prominent examples is Synlab, Europe's largest laboratory chain. The British financial investor Cinven holds approximately 43 percent of the shares in this company[2]. Through numerous acquisitions, Synlab has developed into a leading player in the European laboratory market and recorded significant growth in both revenue and employee numbers between 2010 and 2013[5]. Another significant company in the focus of foreign investors is Amedes, one of the largest laboratory operators in Germany. Amedes is owned by an international consortium consisting of the Canadian Omers Infrastructure, the US investment bank Goldman Sachs, and the French insurer Axa[2]. Previously, Amedes was owned for six years…

more »Foreign Investors Take Over German Laboratory Diagnostics Industry

Generative AI writes love letters

A survey by Telekom reveals: Cupid is out of service. In the future, people will no longer write their love letters themselves but will leave it to Artificial Intelligence (AI) to compose love messages. In France, the USA, and Poland, over 40 percent of respondents would consult tools like ChatGPT, Gemini, and the like for writing love letters. And even in Germany, a respectable 35 percent would use such generative AI for this purpose. This is what YouGov found out on behalf of Deutsche Telekom. People in twelve European countries* (from Germany to Poland, to Sweden and Great Britain, from Greece to France) and the USA were put under the microscope: What would digital assistants based on AI be used for. Valued everyday helpers Digital assistants are developing into valued everyday helpers. Support with very practical problems and organization of…

more »Generative AI writes love letters

Research Center ScaDS.AI: All-Hands Meeting of the AI Community in Dresden

On October 7 and 8, 2024, the national competence center ScaDS.AI Dresden/Leipzig will host the annual All-Hands Meeting of the AI Community in Germany at the OSTRA-DOME and OSTRA-STUDIOS in Dresden. The event will bring together researchers from AI competence and service centers, AI projects, and junior AI groups funded under the German government's AI strategy, other stakeholders from important national and European AI projects, as well as representatives from politics and the media to present current developments and activities. In addition to presenting research and service activities, the All-Hands Meeting of the AI Community in Germany will serve primarily to initiate and strengthen collaborations. Following welcoming remarks by Prof. Ursula Staudinger (Rector of TU Dresden), Prof. Thomas Popp (State Secretary for Digital Administration and Administrative Modernization, Saxon State Chancellery), and Dr. Roland Philippi (State Secretary, Federal Ministry of Education and Research), the AI competence centers will present current highlights from AI research. Within the scope of a poster session, projects by doctoral students will also be presented, virtual… 

more »ScaDS.AI Competence Center: All-Hands Meeting of the AI Community in Dresden

Weight Loss Drugs: Efficacy, Differences, Risks

They are in vogue and promise falling pounds. But are there differences in efficacy between different weight loss drugs? And how do the preparations work? Current studies and research results show that there are indeed differences in efficacy between different weight loss drugs. Tirzepatide (Mounjaro) currently appears to show the strongest effect in weight loss. In studies, it led to an average weight loss of over 20% of body weight[1][2]. Semaglutide (Wegovy, Ozempic) also shows high efficacy with an average weight loss of 15% in clinical studies[1]. Orlistat, an older drug, leads to a significantly lower weight loss of about 3-4 kg compared to placebo[3]. Mechanisms of Action Tirzepatide and Semaglutide belong to the group of GLP-1 receptor agonists. They mimic the effect of the body's own hormone GLP-1, suppress appetite, and slow gastric emptying[2][4]. Orlistat, on the other hand, inhibits fat absorption in the intestine and thus works through a different mechanism[3]. Side Effects and Long-Term Effects… 

more »Weight Loss Drugs: Efficacy, Differences, Risks

Weight Loss Drugs as a Trillion-Dollar Market

  • News

Der Kampf gegen Übergewicht hat sich zu einem der lukrativsten Märkte für die Pharmaindustrie entwickelt. Weltweit leiden rund zwei Milliarden Erwachsene an Übergewicht, davon etwa 650 Millionen an Adipositas. Angesichts dieser Zahlen und der damit verbundenen gesundheitlichen Risiken wie Herz-Kreislauf-Erkrankungen, Diabetes und Nierenprobleme, wetteifern Pharmaunternehmen um die Entwicklung wirksamer Abnehmmittel[5]. An der Spitze dieses Wettbewerbs stehen derzeit die dänische Novo Nordisk und das US-Unternehmen Eli Lilly. Novo Nordisk hat mit seinem Medikament Wegovy, das den Wirkstoff Semaglutid enthält, beeindruckende Ergebnisse erzielt. In klinischen Studien führte Wegovy zu einem durchschnittlichen Gewichtsverlust von 15 Prozent[6]. Das Medikament soll Ende Juli 2024 in Deutschland eingeführt werden, ist jedoch nur für Menschen mit starkem Übergewicht zugelassen[8]. Eli Lilly kontert mit seinem Präparat Mounjaro, das den Wirkstoff Tirzepatid enthält. In Studien zeigte Mounjaro sogar noch stärkere Effekte: Probanden mit einem Gewicht von über 100 Kilogramm… 

more »Abnehmmittel als Billionenmarkt